Related Experiment Video
Updated: Aug 25, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Venous thromboembolism and malignancy
1University of Texas MD Anderson Cancer Center, Department of General Internal Medicine, Ambulatory Treatment & Emergency Care, 1515 Holcombe Blvd., Unit 437, Houston, TX 77030, USA. sgao@mdanderson.org
Abstract:
The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for VTE. Recent developments in moleculobiological studies have indicated that the high risk of VTE in malignancy is attributed to the hypercoagulable state caused by the disease and its treatments. Diagnostic approaches to clinically suspected VTE continue to evolve, making the diagnosis easier and more accurate. Recent advances in clinical studies have refined the management strategies for the prophylaxis and treatment of VTE in patients with or without cancer. In this paper, recent clinical studies will be reviewed, current understanding of the pathogenesis of thrombosis in malignancy described, and clinical implications discussed.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Venous Thrombosis IV: Nursing Management